Spencer Hauck

Journal Article Prostate · March 2024 BACKGROUND: Prostate cancer (PCa) continues to be one of the leading causes of cancer deaths in men. While androgen deprivation therapy is initially effective, castration-resistant PCa (CRPC) often recurs and has limited treatment options. Our previous stu ... Full text Link to item Cite

Heat shock factor 1 directly regulates transsulfuration pathway to promote prostate cancer proliferation and survival.

Journal Article Commun Biol · January 3, 2024 There are limited therapeutic options for patients with advanced prostate cancer (PCa). We previously found that heat shock factor 1 (HSF1) expression is increased in PCa and is an actionable target. In this manuscript, we identify that HSF1 regulates the ... Full text Open Access Link to item Cite

Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer.

Journal Article J Pathol · May 2023 Neuroendocrine (NE) cells comprise ~1% of epithelial cells in benign prostate and prostatic adenocarcinoma (PCa). However, they become enriched in hormonally treated and castration-resistant PCa (CRPC). In addition, close to 20% of hormonally treated tumor ... Full text Link to item Cite

Rewiring of the N-Glycome with prostate cancer progression and therapy resistance.

Journal Article NPJ Precis Oncol · February 24, 2023 An understanding of the molecular features associated with prostate cancer progression (PCa) and resistance to hormonal therapy is crucial for the identification of new targets that can be utilized to treat advanced disease and prolong patient survival. Th ... Full text Link to item Cite

Novel directions of precision oncology: circulating microbial DNA emerging in cancer-microbiome areas.

Journal Article Precision clinical medicine · March 2022 Microbiome research has extended into the cancer area in the past decades. Microbes can affect oncogenesis, progression, and treatment response through various mechanisms, including direct regulation and indirect impacts. Microbiota-associated detection me ... Full text Cite

Myeloid mineralocorticoid receptors contribute to skeletal muscle repair in muscular dystrophy and acute muscle injury.

Journal Article American journal of physiology. Cell physiology · March 2022 Suppressing mineralocorticoid receptor (MR) activity with MR antagonists is therapeutic for chronic skeletal muscle pathology in Duchenne muscular dystrophy (DMD) mouse models. Although mechanisms underlying clinical MR antagonist efficacy for DMD cardiomy ... Full text Cite

Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer.

Journal Article Oncogene · February 2022 Advanced and aggressive prostate cancer (PCa) depends on glutamine for survival and proliferation. We have previously shown that inhibition of glutaminase 1, which catalyzes the rate-limiting step of glutamine catabolism, achieves significant therapeutic e ... Full text Link to item Cite

Targeting therapy-resistant prostate cancer via a direct inhibitor of the human heat shock transcription factor 1.

Journal Article Sci Transl Med · December 16, 2020 Heat shock factor 1 (HSF1) is a cellular stress-protective transcription factor exploited by a wide range of cancers to drive proliferation, survival, invasion, and metastasis. Nuclear HSF1 abundance is a prognostic indicator for cancer severity, therapy r ... Full text Link to item Cite

Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy.

Journal Article ESC heart failure · December 2020 AimsDuchenne muscular dystrophy (DMD) is an X-linked inherited disease due to dystrophin deficiency causing skeletal and cardiac muscle dysfunction. Affected patients lose ambulation by age 12 and usually die in the second to third decades of life ... Full text Cite

Mineralocorticoid receptor antagonists improve membrane integrity independent of muscle force in muscular dystrophy.

Journal Article Human molecular genetics · June 2019 Mineralocorticoid receptor (MR) drugs have been used clinically for decades to treat cardiovascular diseases. MR antagonists not only show preclinical efficacy for heart in Duchenne muscular dystrophy (DMD) models but also improve skeletal muscle force and ... Full text Cite

Mineralocorticoid Receptor Signaling Contributes to Normal Muscle Repair After Acute Injury.

Journal Article Frontiers in physiology · January 2019 Acute skeletal muscle injury is followed by a temporal response of immune cells, fibroblasts, and muscle progenitor cells within the muscle microenvironment to restore function. These same cell types are repeatedly activated in muscular dystrophy from chro ... Full text Cite

Gene expression effects of glucocorticoid and mineralocorticoid receptor agonists and antagonists on normal human skeletal muscle.

Journal Article Physiological genomics · June 2017 Mineralocorticoid and glucocorticoid receptors are closely related steroid hormone receptors that regulate gene expression through many of the same hormone response elements. However, their transcriptional activities and effects in skeletal muscles are lar ... Full text Cite

Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target.

Journal Article FASEB journal : official publication of the Federation of American Societies for Experimental Biology · November 2015 Early treatment with heart failure drugs lisinopril and spironolactone improves skeletal muscle pathology in Duchenne muscular dystrophy (DMD) mouse models. The angiotensin converting enzyme inhibitor lisinopril and mineralocorticoid receptor (MR) antagoni ... Full text Cite